Mariia Stepanechko
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Mariia Stepanechko has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
Awndre Gamache
Department of Pathology, School of Medicine, University of Virginia, USA
1 shared publication- Claire Conarroe
Department of Pathology, School of Medicine, University of Virginia, USA
1 shared publication Frederic Padilla
Focused Ultrasound Foundation, USA
1 shared publication- John A. Hossack
University of Virginia
1 shared publication - Lydia E. Kitelinger
Department of Pathology, University of Virginia, Charlottesville, VA 22908, USA
1 shared publication Madison Nemshick
Department of Pathology, School of Medicine, University of Virginia, USA
1 shared publication
Latest Publications
- Open Access
- 15 May 2025
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Transactions on Biomedical Engineering
- Vol. 72 (11) , 3404-3418
Single Treatment Boiling Histotripsy Focused Ultrasound Ablation Neither Negates nor Enhances the Activity of α-CD40 in a Pancreatic Cancer Model
Objective: Pancreatic adenocarcinoma (PDAC) tumors are often unresectable and do not respond to standard anti-cancer treatments. Boiling histotripsy (BH) is a mechanical focused ultrasound ablation regimen that can target non-operable tumors. BH is a non-invasive procedure that might synergize with immunotherapies being developed for PDAC. We reasoned that BH-mediated release of tumor antigen and damage-associated molecular patterns would augment tumor immunity and cooperate with α-CD40 therapy. Methods: We explored the efficacy of BH ablation either as monotherapy for PDAC or in combination with systemically administered α-CD40 agonistic antibodies in controlling tumor outgrowth. We further assessed the changes in the tumor immune compartment and the ability of BH to release tumor antigens by flow cytometry. Results: A single BH treatment could not control tumor growth and had limited independent immunostimulatory properties. BH effectively liberated tumor antigen into the tumor microenvironment for acquisition by local phagocytes but did not promote its presence in the tumor-draining lymph nodes. BH did not activate either tumor- or lymph node-resident conventional dendritic cells. BH did not impede the ability of α-CD40 immunotherapy to reduce the tumor burden and promote the infiltration of M1-like macrophages and IFN-γ+ CD8+ T cells to the tumor microenvironment, suggesting that antibody access to the ablated tissue was not obstructed. Conclusion: Our findings indicate that PDAC tumor progression cannot be halted by BH ablation using sub-total ablation, and that the BH treatment regimen utilized in this study has limited immunogenicity. Significance: Our discoveries attest to the need for optimizing BH ablation protocols to unlock its anti-tumor potential.
- 15 May 2025
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Transactions on Biomedical Engineering
- Vol. 72 (11) , 3404-3418
Open AccessSingle Treatment Boiling Histotripsy Focused Ultrasound Ablation Neither Negates nor Enhances the Activity of α-CD40 in a Pancreatic Cancer Model
Objective: Pancreatic adenocarcinoma (PDAC) tumors are often unresectable and do not respond to standard anti-cancer treatments. Boiling histotripsy (BH) is a mechanical focused ultrasound ablation regimen that can target non-operable tumors. BH is a non-invasive procedure that might synergize with immunotherapies being developed for PDAC. We reasoned that BH-mediated release of tumor antigen and damage-associated molecular patterns would augment tumor immunity and cooperate with α-CD40 therapy. Methods: We explored the efficacy of BH ablation either as monotherapy for PDAC or in combination with systemically administered α-CD40 agonistic antibodies in controlling tumor outgrowth. We further assessed the changes in the tumor immune compartment and the ability of BH to release tumor antigens by flow cytometry. Results: A single BH treatment could not control tumor growth and had limited independent immunostimulatory properties. BH effectively liberated tumor antigen into the tumor microenvironment for acquisition by local phagocytes but did not promote its presence in the tumor-draining lymph nodes. BH did not activate either tumor- or lymph node-resident conventional dendritic cells. BH did not impede the ability of α-CD40 immunotherapy to reduce the tumor burden and promote the infiltration of M1-like macrophages and IFN-γ+ CD8+ T cells to the tumor microenvironment, suggesting that antibody access to the ablated tissue was not obstructed. Conclusion: Our findings indicate that PDAC tumor progression cannot be halted by BH ablation using sub-total ablation, and that the BH treatment regimen utilized in this study has limited immunogenicity. Significance: Our discoveries attest to the need for optimizing BH ablation protocols to unlock its anti-tumor potential.